A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Trial Details

NCT ID
NCT06868277
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Rilvegostomig
  • Pembrolizumab
Locations (sample)
  • La Mesa, California, United States|32.76783,-117.02308
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Farmington, Connecticut, United States|41.71982,-72.83204
  • Newark, Delaware, United States|39.68372,-75.74966
  • Bay Pines, Florida, United States|27.81419,-82.77816

Key Eligibility Criteria

  • Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes.
  • Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatm…
  • Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Ne…
  • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →